In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

and Mounjaro® (tirzepatide) can help people lose weight, and some — like Wegovy® and Zepbound® — are FDA-approved for those with overweight or obesity and high blood pressure. Your ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

The research also identified changes in glycemic control and cardiometabolic components like lipids and blood pressure. The research found that tirzepatide was generally well-tolerated ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced ... improvements in several health markers, including blood pressure, insulin and lipids, with the effects sustained ...

In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure ...